CORCEPT THERAPEUTICS INC (CORT) Stock Price, Quote, News and Summary
NASDAQ:CORT - Nasdaq - US2183521028 - Common Stock
CORT Quote and Key Statistics
CORCEPT THERAPEUTICS INC
NASDAQ:CORT (1/21/2025, 8:00:00 PM)
After market: 61.11 0 (0%)61.11
+5.8 (+10.49%)
CORT Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 22.56% | ||
| ROA | 18.08% | ||
| ROE | 22.2% | ||
| Debt/Equity | 0 |
CORT Performance and Technical Analysis
CORT Ownership and Analysts
CORT Latest News and Analysis
Exploring NASDAQ:CORT's high growth characteristics.
Is CORCEPT THERAPEUTICS INC (NASDAQ:CORT) suited for high growth investing?
Exploring the Growth Potential of NASDAQ:CORT as It Nears a Breakout.
CORCEPT THERAPEUTICS INC (NASDAQ:CORT), a strong growth stock, setting up for a breakout.
NASDAQ:CORT is not too expensive for the growth it is showing.
For those who appreciate growth without the sticker shock, NASDAQ:CORT is worth considering.
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.
Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients With Hypercortisolism
Corcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism
About CORT
Company Profile
Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company. The company is headquartered in Redwood City, California and currently employs 352 full-time employees. The company went IPO on 2004-04-15. The firm operates through the discovery, development and commercialization of the pharmaceutical products segment. The firm has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, exicorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
Company Info
CORCEPT THERAPEUTICS INC
101 Redwood Shores Parkway
Redwood City CALIFORNIA 94025 US
CEO: Joseph K. Belanoff
Employees: 352
Company Website: https://www.corcept.com/
Investor Relations: https://ir.corcept.com/investor-relations
Phone: 16506888803
CORT Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 72.99 | 704.73B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.38 | 359.88B | ||
| JNJ | JOHNSON & JOHNSON | 14.47 | 356.69B | ||
| MRK | MERCK & CO. INC. | 16.17 | 243.45B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 17.84 | 210.75B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.37 | 199.39B | ||
| PFE | PFIZER INC | 10.33 | 150.97B | ||
| SNY | SANOFI-ADR | 12.43 | 129.60B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.75 | 115.69B | ||
| ZTS | ZOETIS INC | 29.09 | 75.58B | ||
| GSK | GSK PLC-SPON ADR | 8.26 | 68.92B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 21.83 | 41.53B |